Abstract:Lipid nanoparticles (LNPs) have successfully entered the clinic for the delivery of mRNA- and siRNA-based therapeutics, most recently as vaccines for COVID-19. Nevertheless, there is a lack of understanding regarding their in vivo behavior, in particular cell targeting. Part of this LNP tropism is based on the adherence of endogenous protein to the particle surface. This protein forms a so-called corona that can change, amongst other things, the circulation time, biodistribution and cellular uptake of these particles. The formation of this protein corona, in turn, is dependent on the nanoparticle properties (e.g., size, charge, surface chemistry and hydrophobicity) as well as the biological environment from which it is derived. With the potential of gene therapy to target virtually any disease, administration sites other than intravenous route are considered, resulting in tissue specific protein coronas. For neurological diseases, intracranial administration of LNPs results in a cerebral spinal fluid derived protein corona, possibly changing the properties of the lipid nanoparticle compared to intravenous administration. Here, the differences between plasma and CSF derived protein coronas on a clinically relevant LNP formulation were studied in vitro. Protein analysis showed that LNPs incubated in human CSF (C-LNPs) developed a protein corona composition that differed from that of LNPs incubated in plasma (P-LNPs). Lipoproteins as a whole, but in particular apolipoprotein E, represented a higher percentage of the total protein corona on C-LNPs than on P-LNPs. This resulted in improved cellular uptake of C-LNPs compared to P-LNPs, regardless of cell origin. Importantly, the higher LNP uptake did not directly translate into more efficient cargo delivery, underlining that further assessment of such mechanisms is necessary. These findings show that biofluid specific protein coronas alter LNP functionality, suggesting that the site of administration could affect LNP efficacy in vivo and needs to be considered during the development of the formulation.

Serum-derived Protein Coronas Affect Nanoparticle Interactions with Brain Cells

Protein Coronas Derived from Cerebrospinal Fluid Enhance the Interactions Between Nanoparticles and Brain Cells

Biofluid specific protein coronas affect lipid nanoparticle behavior in vitro

Protein Corona Formation on Colloidal Polymeric Nanoparticles and Polymeric Nanogels: Impact on Cellular Uptake, Toxicity, Immunogenicity, and Drug Release Properties

Biological Effects of Formation of Protein Corona Onto Nanoparticles

Towards understanding of nanoparticle–protein corona

An Overview of Nanoparticle Protein Corona Literature

Unmasking CSF protein corona: Effect on targeting capacity of nanoparticles

Protein corona on brain targeted nanocarriers: Challenges and prospects

The Effects of Serum Albumin Pre-Adsorption of Nanoparticles on Protein Corona and Membrane Interaction: A Molecular Simulation Study

The protein corona and its effects on nanoparticle-based drug delivery systems

Characterization and Biomedical Application Opportunities of the Nanoparticle's Protein Corona

Corona of Thorns: the Surface Chemistry-Mediated Protein Corona Perturbs the Recognition and Immune Response of Macrophages

Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts

Artificial engineering of the protein corona at bio-nano interfaces for improved cancer-targeted nanotherapy

Protein corona of nanoparticles: distinct proteins regulate the cellular uptake.

Protein corona potentiates recovery of nanoparticle-induced disrupted tight junctions in endothelial cells

Effect of Protein Corona on the Specificity and Efficacy of Nanobioconjugates to Treat Intracellular Infections

Interplay Between Nanomedicine And Protein Corona

The role of patient-specific variables in protein corona formation and therapeutic efficacy in nanomedicine

Nanoparticle protein corona: from structure and function to therapeutic targeting